Clinical Trial Search

Primary: Mortality — 4356; 1919 Participants

Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants

Primary: Total Number of Medications — 15; 16; 13; 15 Medications — p=0.017

Primary: Measured Adherence to GDMT by Pill Count — 74.6; 83.3 adherence ratio expressed in %

Primary: Medication Possession Ratio at Baseline — 65.0 percentage of medication possession

Primary: Clinical Global Impression — 4.07; 3.96 units on a scale — p=<0.05

Primary: Percentage of Potentially Inappropriate Galenic Units — 24; 23 percent — p=<0.05

Primary: Medication Adherence — 91.2; 85.5 percentage of days covered

Primary: Change in Total Standardized Daily Dosage (TSDD) of CNS-Active Medications From Baseline to 4 Months, as Measured in the EHR — 9.0; 9.0; -1.3; -1.6 doses per day

Primary: Low Density Lipoprotein - Cholesterol — -6.74; 0.53 mg/dL — p=0.27

Primary: Reduction of the Estimated 10-year Total Cardiovascular Risk Score — 11.5; 11.1 percent

Primary: Medication Adherence - Pill Count — 0.46; 0.53 Probability of adherence (PT/PP => 0.8) — p=0.04

Primary: Mini-mental State Examination (MMEE) — 12; 12 score — p=0.23

Primary: Time to Dispensing of Inappropriate Medication Prescription — 76.7; 77.9; 77.5 Percentage of Cumulative Incidence — p=0.76

Primary: Preliminary Efficacy of the Intervention to be Assessed From Primary Care Clinician's Intervention Visit Clinical Notes and EHR — 15; 7; 7; 7 Participants

Primary: Medication Adherence — 21.6; 23.8 score on a scale

Primary: Blood Pressure Medication Adherence — 396; 470 Participants — p=0.0103

Primary: Percent of Participants With Adherence at Month 6 — 91; 40 percent persistent on therapy — p=<0.05

Primary: Number of Inappropriate Medication at Follow-up — 4.35; 4.85 drugs — p=0.723

Primary: Change in Inappropriate Prescribing by Study Arm: Descriptive Comparison Across Study Arms — 35.2; 33; 35.6; 40.6 percentage of patients

Primary: Hospital Length of Stay — 6.8; 7.8; 7.5 Days

Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001

Primary: Major Cardiovascular Adverse Events (MACE) — 156; 118 number of adjudicated events — p=< 0.025

Primary: Enrollment to Assess Feasibility — 50 Participants

Primary: Change in Past 6 Month Non-Medical Use of Prescription Stimulant Medication Frequency — -2.04; -1.72; -1.03; -.38 Usage days — p=0.03

Primary: Count of Referrals to Non-opioid Care — 3.075; 3.61 Count of referrals — p=0.213

Primary: Number of Serious Medication Errors as Determined by Interview and Medical Chart Review — 0.95; 0.87 serious medication errors

Primary: Number of Patients Readmitted Because of Drug Related Reasons — 40; 50 Participants

Primary: Characterisation of Medication Levels — 5.54; 2.18; 1.81; 1.53 MOM

Primary: Mean Severity-weighted Admission Medication History (AMH) Error Score — 23; 4.1; 4.1 Mean Severity-weighted AMH Error Score